Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – William Blair reduced their FY2019 earnings per share estimates for shares of Biohaven Pharmaceutical in a report released on Tuesday, August 13th. William Blair analyst T. Lugo now anticipates that the company will earn ($6.94) per share for the year, down from their previous estimate of ($5.83).

Biohaven Pharmaceutical (NYSE:BHVN) last announced its earnings results on Thursday, August 8th. The company reported ($2.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.09) by ($0.26).

Several other brokerages have also issued reports on BHVN. Needham & Company LLC lifted their target price on shares of Biohaven Pharmaceutical to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 8th. Morgan Stanley set a $50.00 target price on shares of Biohaven Pharmaceutical and gave the company a “hold” rating in a research report on Friday, August 9th. Zacks Investment Research lowered shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, July 19th. Oppenheimer set a $68.00 target price on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Wednesday, June 19th. Finally, Piper Jaffray Companies lifted their target price on shares of Biohaven Pharmaceutical from $75.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, May 8th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Biohaven Pharmaceutical currently has a consensus rating of “Buy” and an average price target of $69.55.

Shares of NYSE BHVN opened at $39.22 on Thursday. The company’s 50-day simple moving average is $42.48 and its 200-day simple moving average is $50.30. Biohaven Pharmaceutical has a 52-week low of $29.17 and a 52-week high of $67.86. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of -6.38 and a beta of 0.24.

A number of large investors have recently bought and sold shares of BHVN. Manchester Capital Management LLC acquired a new position in Biohaven Pharmaceutical in the 1st quarter valued at about $52,000. Tower Research Capital LLC TRC acquired a new position in Biohaven Pharmaceutical in the 2nd quarter valued at about $65,000. Aperio Group LLC acquired a new position in Biohaven Pharmaceutical in the 2nd quarter valued at about $71,000. Glen Harbor Capital Management LLC boosted its holdings in Biohaven Pharmaceutical by 165.9% in the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock valued at $76,000 after purchasing an additional 1,088 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Biohaven Pharmaceutical by 94.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,256 shares of the company’s stock valued at $99,000 after purchasing an additional 1,097 shares during the last quarter. Institutional investors own 85.14% of the company’s stock.

In other Biohaven Pharmaceutical news, CFO James Engelhart purchased 2,500 shares of the stock in a transaction that occurred on Thursday, June 27th. The shares were purchased at an average cost of $43.05 per share, for a total transaction of $107,625.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John W. Childs purchased 10,000 shares of the stock in a transaction that occurred on Wednesday, June 26th. The shares were acquired at an average price of $40.37 per share, for a total transaction of $403,700.00. The disclosure for this purchase can be found here. Insiders have purchased 17,500 shares of company stock worth $712,425 over the last 90 days. 23.90% of the stock is currently owned by company insiders.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Recommended Story: Stop Order

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.